News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
486,188 Results
Type
Article (8061)
Company Profile (142)
Press Release (478254)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166777)
Career Advice (303)
Deals (25746)
Drug Delivery (7)
Drug Development (52928)
Employer Resources (14)
FDA (9765)
Job Trends (8580)
News (238297)
Policy (17900)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (489)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (98)
Alliances (33148)
ALS (113)
Alzheimer's disease (987)
Antibody-drug conjugate (ADC) (287)
Approvals (10413)
Artificial intelligence (342)
ASCO (160)
Autoimmune disease (224)
Automation (29)
Bankruptcy (263)
Belgium (2)
Best Places to Work (6961)
BIO (36)
Biologics (10)
BIOSECURE Act (1)
Biosimilars (116)
BioSpace Insights (17)
Biotechnology (90)
Bispecific (1)
Bladder cancer (140)
Brain cancer (31)
Breast cancer (521)
Cancer (3794)
Cardiovascular disease (227)
Career advice (242)
Career pathing (1)
CAR-T (180)
CDC (1)
CDMO (20)
Celiac Disease (1)
Cell therapy (493)
Cervical cancer (35)
Clinical research (48072)
Collaboration (1293)
Commercialization (3)
Compensation (1539)
Complete response letters (34)
COVID-19 (762)
CRISPR (64)
C-suite (811)
Cystic fibrosis (87)
Data (5919)
Denatured (4)
Depression (107)
Dermatology (71)
Diabetes (363)
Diagnostics (4227)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (160)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (167)
Earnings (73764)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88179)
Executive appointments (716)
FDA (12517)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (19)
Frontotemporal dementia (24)
Funding (958)
Gene editing (126)
Generative AI (11)
Gene therapy (335)
GLP-1 (296)
Government (947)
Grass and pollen (2)
Guidances (281)
Healthcare (9365)
Hematology (94)
HIV (55)
Huntington's disease (23)
IgA nephropathy (70)
Immunology and inflammation (108)
Immuno-oncology (61)
Indications (164)
Infectious disease (954)
Inflammatory bowel disease (131)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (265)
Interviews (41)
IPO (12391)
IRA (2)
Job creations (1968)
Job search strategy (232)
JPM (1)
Kidney cancer (17)
Kidney disease (46)
Labor market (2)
Layoffs (61)
Legal (5196)
Licensing (20)
Liver cancer (45)
Longevity (20)
Lung cancer (551)
Lymphoma (259)
Machine learning (29)
Management (3)
Manufacturing (580)
Marketing (8)
MASH (120)
Medical affairs (2)
Medical device (8680)
Medtech (8840)
Mergers & acquisitions (14424)
Metabolic disorders (738)
mRNA (65)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (228)
Neuropsychiatric disorders (40)
Neuroscience (1883)
NextGen: Class of 2026 (3150)
Non-profit (844)
Obesity (234)
Opinion (11)
Ovarian cancer (163)
Pain (179)
Pancreatic cancer (207)
Parkinson's disease (207)
Partnered (12)
Patents (505)
Patient recruitment (534)
Patient selection (4)
Peanut (32)
People (41388)
Peptides (3)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15525)
Phase 2 (21479)
Phase 3 (14487)
Pipeline (7819)
Policy (18)
Postmarket research (1560)
Preclinical (6563)
Press Release (34)
Prostate cancer (194)
Psychedelics (8)
Radiopharmaceuticals (195)
Rare diseases (593)
Real estate (3023)
Recruiting (6)
Regenerative medicine (5)
Regulatory (14984)
Reports (24)
Research institute (585)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (104)
Series A (165)
Series B (123)
Service/supplier (5)
Sickle cell disease (63)
Special edition (1)
Spinal muscular atrophy (91)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (51)
Vaccines (320)
Venture capital (17)
Weight loss (75)
Women's health (90)
Date
Last 7 days (293)
Last 30 days (1401)
Last 365 days (19036)
2026 (13928)
2025 (19261)
2024 (23004)
2023 (26560)
2022 (34597)
2021 (37189)
2020 (33472)
2019 (23266)
2018 (17487)
2017 (18755)
2016 (17903)
2015 (24266)
2014 (21675)
2013 (18129)
2012 (20203)
2011 (20443)
2010 (20316)
Location
Africa (229)
Alabama (80)
Alaska (2)
Arizona (312)
Arkansas (11)
Asia (18027)
Australia (2111)
California (12432)
Canada (3260)
China (555)
Colorado (504)
Connecticut (428)
Delaware (216)
Europe (24745)
Florida (1868)
Georgia (393)
Hawaii (3)
Idaho (46)
Illinois (734)
India (53)
Indiana (326)
Iowa (16)
Japan (431)
Kansas (104)
Kentucky (32)
Louisiana (28)
Maine (26)
Maryland (1236)
Massachusetts (8139)
Michigan (315)
Minnesota (573)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (125)
New Hampshire (60)
New Jersey (2718)
New Mexico (12)
New York (2916)
North Carolina (1322)
North Dakota (4)
Northern California (6250)
Ohio (297)
Oklahoma (14)
Oregon (16)
Pennsylvania (2311)
Puerto Rico (23)
Rhode Island (30)
South America (406)
South Carolina (78)
South Dakota (1)
Southern California (5182)
Tennessee (125)
Texas (2029)
United States (40288)
Utah (377)
Vermont (1)
Virginia (159)
Washington D.C. (39)
Washington State (960)
West Virginia (1)
Wisconsin (75)
Wyoming (1)
486,188 Results for "fibrogen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
September 3, 2025
·
4 min read
Mergers & acquisitions
AstraZeneca Buys FibroGen’s China Unit for $160M as Probes Continue
A year ago, AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.
February 20, 2025
·
2 min read
·
Tristan Manalac
Press Releases
FibroGen to Report Third Quarter 2025 Financial Results
November 3, 2025
·
1 min read
Press Releases
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
December 3, 2025
·
1 min read
Press Releases
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
August 18, 2025
·
2 min read
Press Releases
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
November 10, 2025
·
11 min read
Press Releases
FibroGen to Report Second Quarter 2025 Financial Results
August 5, 2025
·
1 min read
Biotech Bay
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron’s anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors.
June 3, 2024
·
5 min read
Biotech Bay
FibroGen to Participate in Upcoming May 2024 Investor Conferences
FibroGen, Inc. announced that the company’s management will participate in the following investor conferences.
May 7, 2024
·
1 min read
Press Releases
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
·
11 min read
1 of 48,619
Next
